

PROGRAMME

LEIPZIG INTERVENTIONAL COURSE

L I N C



Renu Virmani

Page 1/6

Wednesday, January 28, 2015

GLOBAL EXPERT EXCHANGE

08:00 – 10:00 **Catheter-based treatment of hypertension, heart failure and beyond – where do we stand, where do we go?**

CHAIRMAN:

Felix Mahfoud
Horst Sievert

MODERATOR:

Thomas Zeller
Paul Sobotka
Roland Schmieder
Michael Böhm
Oliver Vonend

08:00 – 08:07 Renal denervation: what has anatomy taught us?

Renu Virmani

08:07 – 08:14 From bench to bedside: how and where to treat the renal artery?

Felix Mahfoud

08:14 – 08:21 How does renal artery anatomy effect the outcome of RDN procedures?

Britta Vogel

08:21 – 08:28 What to learn from recent clinical trials: Symplicity HTN-3, FRENCH-DENERV-HTN, PRAGUE-15?

Thomas Zeller

08:28 – 08:35 Renal denervation – dead or alive? The view point of a nephrologist/hypertension specialist

Oliver Vonend

08:35 – 08:42 Recent clinical findings and how they changed my patient selection: who is the ideal candidate?

Philipp Lurz

08:42 – 08:49 What is needed now? New clinical trials that would change my clinical practice

Roland Schmieder

08:49 – 08:56 Renal denervation in patients with impaired kidney function – results from the Heidelberg RDN registry

Erwin Blessing

08:56 – 09:03 Late results of radiofrequency denervation and assessment of vessel patency

Yvonne Bausback

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Renu Virmani

Page 2/6

Wednesday, January 28, 2015

- | | |
|---------------|---|
| 09:03 – 09:10 | Preliminary results of RETREAT (renal denervation with ultrasound after failed radiofrequency denervation)
Horst Sievert |
| 09:10 – 09:17 | Going to the source: A disruptive approach to renal denervation with the non-vascular Verve system
Richard Heuser |
| 09:17 – 09:24 | Turn the page for hypertension and lets go for heart failure and arrhythmias
Michael Böhm |
| 09:24 – 09:31 | Blood pressure-lowering interventions beside renal denervation – what is on the horizon?
Horst Sievert |
| 09:31 – 09:38 | Treatment of resistant hypertension by creation of an AV anastomosis: the pathophysiologic basis and principle of treatment
Paul Sobotka |
| 09:38 – 09:45 | Orchestrating sympathovagal balance with Barostim
Navid Madershahian |
| 09:45 – 09:52 | Barostim: Clinical evidence in resistant hypertension and heart failure
Jochen Müller-Ehmsen |
| 09:52 – 10:00 | Discussion and conclusion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Renu Virmani

Page 3/6

Wednesday, January 28, 2015

MAIN ARENA 1

09:30 – 11:00 **Critical limb ischemia treatment 2014: Lessons learned, current status and future perspectives**

CHAIRMAN:

Dierk Scheinert
Peter Schneider

MODERATOR:

Iris Baumgartner
Renu Virmani
Andrew Holden
Yoshiaki Yokoi
Michael Jaff

- 09:30 – 09:35 The rationale for the “Endovascular First” concept and how to implement it
Peter Schneider
- 09:35 – 09:40 Real world CLI practice: Update from the CRITISCH registry
Theodosios Bisdas
- 09:40 – 10:10 The Angiosome concept: Pro and cons
- 09:40 – 09:45 The BEST-CLI Trial: Open vs. endovascular therapy for critical limb ischemia
Michael Jaff
- 09:45 – 09:50 Revascularization of the wound-related artery is key
Osamu Iida
- 09:50 – 10:00 Live case transmission from Leipzig part I
- 10:00 – 10:05 There is no proof for the angiosome concept
Peter Huppert
- 10:05 – 10:10 Panel discussion and vote
- 10:10 – 11:00 Drug-coated balloons for BTK disease in critical limb ischemia – a failed concept?
- 10:10 – 10:15 One year after In.Pact Deep: Lessons learned from a failed trial
Thomas Zeller
- 10:15 – 10:20 Safety of Paclitaxel balloon coatings: Insights from a pathologist
Renu Virmani

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Renu Virmani

Page 4/6

Wednesday, January 28, 2015

- | | |
|---------------|--|
| 10:20 – 10:25 | Ongoing trials and future concepts for local drug delivery in BTK arteries
Dierk Scheinert |
| 10:25 – 10:30 | Panel discussion and vote |
| 10:30 – 10:45 | Live case transmission from Leipzig part II |
| 10:45 – 10:50 | Destiny II: 12 months results with long segment DES treatment in BTK arteries
Marc Bosiers |
| 10:50 – 10:55 | PES BTK 70: 12 months results with a paclitaxel-coated self-expandingstent in BTK arteries
Marc Bosiers |
| 10:55 – 11:00 | Initial experience with absorbable drug-eluting vascular scaffolds in BTK arteries
Ramon Varcoe |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Renu Virmani

Page 5/6

Wednesday, January 28, 2015

MAIN ARENA 1

- 13:30 – 15:00** **Symposium: Lutonix® DCB – Discussion on pre-clinical safety studies, new insights from LEVANT2, Real World experience and the role of DCB in treatment of critical limb ischemia**
supported with an educational grant from CR BARD
CHAIRMAN:
Michael Jaff
MODERATOR:
Renu Virmani
Marcus Thieme
Marianne Brodmann
Jihad Mustapha
- 13:30 – 13:37 Not all DCBs are created equal: Side by side pre-clinical safety evaluation of leading DCBs
Renu Virmani
- 13:37 – 14:02 Live case transmission from Leipzig
- 14:02 – 14:09 New insights from LEVANT2: Randomized 12 month data and post hoc analysis
Dierk Scheinert
- 14:09 – 14:16 A first look and interim analysis of 12 month outcomes from the Real World Global SFA registry
Marcus Thieme
- 14:16 – 14:40 Live case transmission from Leipzig
- 14:40 – 14:47 Role of DCBs in treating critical limb ischemia and the enrollment update on-going Lutonix® BTK clinical trial
Marianne Brodmann
- 14:47 – 14:54 Discussion on physiology of CLI in utility of DCB in below-the-knee procedures
Jihad Mustapha
- 14:54 – 15:00 German single center experience with Lutonix® DCB in BTK
Sabine Steiner

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Renu Virmani

Page 6/6

Thursday, January 29, 2015

DISCUSSION FORUM

- 12:30 – 13:30** **The great debate: Are all DCB equal?**
CHAIRMAN:
Michael Jaff
Dierk Scheinert
DISCUSSANT:
Gunnar Tepe
Renu Virmani
Stephan Duda
Marianne Brodmann
- 12:30 – 12:37 There are clear differences in DCB outcomes in the SFA for various coatings – DCB are not equal!
Gunnar Tepe
- 12:37 – 12:44 Lacking head-to-head trials comparing different DCB studies is comparing apples and oranges –
Results have been substantially affected by trial design
- 12:44 – 12:51 The relevance of Paclitaxel dose and coating for efficacy and safety
Renu Virmani
- 12:51 – 12:58 Whats next to come in the drug delivery space: Ongoing DCB programmes
Stephan Duda
- 12:58 – 13:05 Lessons learned from INPACT.Deep and why we should stay away from DCB for BTK interventions
Erich Minar
- 13:05 – 13:12 DCB are still a valid option to solve the challenge of BTK vessel patency: Lutonix BTK trials are
continuing
Marianne Brodmann
- 13:12 – 13:30 Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.